SCHEMBL18038974

SCHEMBL18038974

O=C(Cn1cc(S(=O)(=O)N2CCCC2)ccc1=O)c1cccc(-c2ccc(Cc3ccccc3)cc2)c1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ ALDH1A1 P00352 4/20 0.46
▸ GAA P10253 1/20 0.46
▸ PARP1 P09874 1/20 0.43
▸ GRIN2B Q13224 3/20 0.43
▸ AKR1C3 P42330 1/20 0.42
▸ AKR1C1 Q04828 1/20 0.42
▸ USP2 O75604 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ IL1RN P18510 1/20 0.42
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18038951 0.94 L3MBTL1 (0.52) L3MBTL1ALDH1A1GAAGRIN2BAKR1C3
SCHEMBL18038979 0.94 L3MBTL1 (0.52) L3MBTL1ALDH1A1GAAGRIN2BAKR1C3
SCHEMBL18038943 0.93 L3MBTL1 (0.53) L3MBTL1ALDH1A1GAAGRIN2BAKR1C3
SCHEMBL18038990 0.92 L3MBTL1 (0.52) L3MBTL1ALDH1A1GAAGRIN2BAKR1C3
SCHEMBL18039014 0.91 L3MBTL1 (0.52) L3MBTL1ALDH1A1GAAGRIN2BAKR1C3
SCHEMBL18039012 0.91 L3MBTL1 (0.49) L3MBTL1ALDH1A1GAAUSP2MAPK1
SCHEMBL18038965 0.88 L3MBTL1 (0.52) L3MBTL1ALDH1A1GAAAKR1C3AKR1C1
SCHEMBL18038976 0.88 L3MBTL1 (0.48) L3MBTL1ALDH1A1GAAAKR1C3AKR1C1
SCHEMBL18038989 0.86 L3MBTL1 (0.56) L3MBTL1ALDH1A1GAAMEN1KMT2A
SCHEMBL18038954 0.86 L3MBTL1 (0.56) L3MBTL1ALDH1A1GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11311523-B2 Pyridinone compound and use thereof KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2022-04-26 — — US disclosed
EP-3692992-A1 METHOD OF SCREENING DOCK1-SELECTIVE INHIBITORS FOR CANCER TREATMENT Kyushu University National University Corporation (JP) 2020-08-12 — — EP disclosed
EP-3263133-B1 PYRIDINONE COMPOUND AND USE THEREOF UNIV KYUSHU NAT UNIV CORP (JP) 2020-04-01 — — EP disclosed
US-20200061039-A1 PYRIDINONE COMPOUND AND USE THEREOF KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2020-02-27 — — US disclosed
US-10406141-B2 Pyridinone compound and use thereof KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2019-09-10 — — US disclosed
US-20180028515-A1 PYRIDINONE COMPOUND AND USE THEREOF KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2018-02-01 — — US disclosed
EP-3263133-A1 PYRIDINONE COMPOUND AND USE THEREOF Kyushu University, National University Corporation (JP) 2018-01-03 — — EP disclosed
WO-2016136985-A1 PYRIDINONE COMPOUND AND USE THEREOF 国立大学法人九州大学 2016-09-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180028515-A1 PYRIDINONE COMPOUND AND USE THEREOF DOCK5, DOCK2, CIB1 L3MBTL1 2983/4885ALDH1A1 52/4885GAA 4692/4885
US-20200061039-A1 PYRIDINONE COMPOUND AND USE THEREOF DOCK5, DOCK2, CIB1 L3MBTL1 2940/4885ALDH1A1 49/4885GAA 4691/4885
US-10406141-B2 Pyridinone compound and use thereof DOCK5, DOCK2, CIB1 L3MBTL1 2983/4885ALDH1A1 52/4885GAA 4692/4885
US-11311523-B2 Pyridinone compound and use thereof DOCK5, DOCK2, CIB1 L3MBTL1 2940/4885ALDH1A1 49/4885GAA 4691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback